The vulnerable patient: Refocusing on the plaque?

Thrombosis and Haemostasis

Volumn 102, Issue 2, 2009, Pages 231-239

  Eijgelaar, Wouter J ^a   Heeneman, Sylvia ^a   Daemen, Mat J A P ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Atherosclerosis; Biomarkers; Cardiovascular event prediction; Imaging; Risk factors

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CD40 LIGAND; COLONY STIMULATING FACTOR 1; FIBRINOGEN; GELATINASE B; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN 8; AUTACOID;

ACUTE CORONARY SYNDROME; AGE; ATHEROSCLEROTIC PLAQUE; BODY MASS; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DISEASE MARKER; HIGH RISK PATIENT; HUMAN; HYPERTENSION; PHENOTYPE; PRIORITY JOURNAL; STROKE; ATHEROSCLEROSIS; BLOOD; METABOLISM; PATHOLOGY; REVIEW; RISK FACTOR; RUPTURE;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; HUMANS; INFLAMMATION MEDIATORS; RISK FACTORS; RUPTURE, SPONTANEOUS; STROKE;

EID: 70350452078     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-01-0030     Document Type: Conference Paper

References (95)

1. Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol 2006; 47: C7-12.
2. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 2003; 108: 1772-1778. (Pubitemid 37296082)
3. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003; 108: 1664-1672. (Pubitemid 37243650)
4. Thim T, Hagensen MK, Bentzon JF, et al. From vulnerable plaque to atherothrombosis. J Intern Med 2008; 263: 506-516.
5. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25-146.
6. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart Disease and Stroke Statistics-2009 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008.
7. Naghavi M, Falk E, Hecht HS, et al. From vulnerable plaque to vulnerable patient-Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol 2006; 98: 2H-15H. (Pubitemid 44523760)
8. Hellings WE, Peeters W, Moll FL, et al. From vulnerable plaque to vulnerable patient: the search for biomarkers of plaque destabilization. Trends Cardiovasc Med 2007; 17: 162-171. (Pubitemid 46898844)
9. Weintraub HS. Identifying the vulnerable patient with rupture-prone plaque. Am J Cardiol 2008; 101: 3F-10F.
10. Mallat Z, Tedgui A. Cytokines as regulators of atherosclerosis in murine models. Curr Drug Targets 2007; 8: 1264-1272.
11. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006; 86: 515-581.
12. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126.
13. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008; 54: 24-38. (Pubitemid 351182593)
14. Kannel WB, Dawber TR, Kagan A, et al. Factors of risk in the development of coronary heart disease-six year follow-up experience. The Framingham Study. Ann Intern Med 1961; 55: 33-50.
15. Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998; 19 (Suppl A): A2-11.
16. Akosah KO, Schaper A, Cogbill C, et al. Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform? J Am Coll Cardiol 2003; 41: 1475-1479.
17. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486-2497.
18. Sheridan S, Pignone M, Mulrow C. Framingham-based tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians. J Gen Intern Med 2003; 18: 1039-1052. (Pubitemid 38091400)
19. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002; 105: 310-315. (Pubitemid 34106178)
20. Buffon A, Biasucci LM, Liuzzo G, et al. Wide-spread coronary inflammation in unstable angina. N Engl J Med 2002; 347: 5-12. (Pubitemid 34728951)
21. Burke AP, Farb A, Malcom GT, et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336: 1276-1282. (Pubitemid 27187780)
22. Mann J, Davies MJ. Mechanisms of progression in native coronary artery disease: role of healed plaque disruption. Heart 1999; 82: 265-268. (Pubitemid 29429594)
23. Goldstein JA, Demetriou D, Grines CL, et al. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000; 343: 915-922. (Pubitemid 30727803)
24. Nissen SE. Who is at risk for atherosclerotic disease? Lessons from intravascular ultrasound. Am J Med 2002; 112 (Suppl 8A): 27S-33S.
25. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 1990; 65: 168-172.
26. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331: 417-424. (Pubitemid 24247397)
27. Lowe GD, Pepys MB. C-reactive protein and cardiovascular disease: weighing the evidence. Curr Atheroscler Rep 2006; 8: 421-428. (Pubitemid 44340187)
28. Danesh J, Erqou S, Walker M, et al. The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol 2007; 22: 839-869.
29. Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997; 17: 1121-1127.
30. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-733. (Pubitemid 28391836)
31. Jager A, van Hinsbergh VW, Kostense PJ, et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol 1999; 19: 3071-3078.
32. Mendall MA, Strachan DP, Butland BK, et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000; 21: 1584-1590. (Pubitemid 30736155)
33. Casas JP, Shah T, Hingorani AD, et al. C-reactive protein and coronary heart disease: a critical review. J Intern Med 2008; 264: 295-314.
34. Hanriot D, Bello G, Ropars A, et al. C-reactive protein induces pro- and anti-inflammatory effects, including activation of the liver X receptor alpha, on human monocytes. Thromb Haemost 2008; 99: 558-569. (Pubitemid 351549293)
35. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397. (Pubitemid 38419992)
36. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-1772. (Pubitemid 30213096)
37. Ikonomidis I, Stamatelopoulos K, Lekakis J, et al. Inflammatory and non-invasive vascular markers: the multimarker approach for risk stratification in coronary artery disease. Atherosclerosis 2008; 199: 3-11.
38. Tan J, Hua Q, Gao J, et al. Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and tissue inhibitor of metalloproteinase- 1 in patients with acute ST-segment elevation myocardial infarction. Clin Cardiol 2008; 31: 413-418.
39. Oren H, Erbay AR, Balci M, et al. Role of novel biomarkers of inflammation in patients with stable coronary heart disease. Angiology 2007; 58: 148-155. (Pubitemid 46669102)
40. Inoue T, Komoda H, Nonaka M, et al. Interleukin-8 as an independent predictor of long-term clinical outcome in patients with coronary artery disease. Int J Cardiol 2008; 124: 319-325. (Pubitemid 351305383)
41. Ikonomidis I, Andreotti F, Economou E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999; 100: 793-798. (Pubitemid 29398875)
42. Saremi A, Anderson RJ, Luo P, et al. Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis 2009; 203: 610-614..
43. Gotsman I, Stabholz A, Planer D, et al. Serum cytokine tumor necrosis factor-alpha and interleukin-6 associated with the severity of coronary artery disease: indicators of an active inflammatory burden? Isr Med Assoc J 2008; 10: 494-498.
44. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 2631-2639. (Pubitemid 44969122)
45. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358: 2148-2159.
46. Pasterkamp G, Daemen M. Circulating cells: the biofactory for markers of atherosclerotic disease. Eur Heart J 2008; 29: 2701-2702.
47. Schirmer SH, Fledderus JO, van der Laan AM, et al. Suppression of inflammatory signaling in monocytes from patients with coronary artery disease. J Mol Cell Cardiol 2009; 46: 177-185..
48. Ganesh SK, Skelding KA, Mehta L, et al. Rationale and study design of the CardioGene Study: genomics of in-stent restenosis. Pharmacogenomics 2004; 5: 952-1004. (Pubitemid 39386759)
49. Patino WD, Kang JG, Matoba S, et al. Atherosclerotic plaque macrophage transcriptional regulators are expressed in blood and modulated by tristetraprolin. Circ Res 2006; 98: 1282-1289. (Pubitemid 43948083)
50. Hurks R, Peeters W, Derksen WJ, et al. Biobanks and the search for predictive biomarkers of local and systemic outcome in atherosclerotic disease. Thromb Haemost 2009; 101: 48-54.
51. Cleutjens KB, Faber BC, Rousch M, et al. Non-invasive diagnosis of ruptured peripheral atherosclerotic lesions and myocardial infarction by antibody profiling. J Clin Invest 2008; 118: 2979-2985.
52. Narula J, Garg P, Achenbach S, et al. Arithmetic of vulnerable plaques for noninvasive imaging. Nat Clin Pract Cardiovasc Med 2008; 5 (Suppl 2): S2-10.
53. Naghavi M, Falk E, Hecht HS, et al. The First SHAPE (Screening for Heart Attack Prevention and Education) Guideline. Crit Pathw Cardiol 2006; 5: 187-190. (Pubitemid 44912338)
54. Sitzer M. Atherosclerotic carotid stenosis and occlusion. Front Neurol Neurosci 2006; 21: 36-56.
55. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-tomoderate coronary artery disease? Circulation 1988; 78: 1157-1166.
56. Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988; 12: 56-62. (Pubitemid 18158024)
57. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1991; 325: 445-453.
58. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998; 351: 1379-1387.
59. Budoff MJ, Achenbach S, Blumenthal RS, et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation 2006; 114: 1761-1791. (Pubitemid 44607126)
60. Mitsutake R, Niimura H, Miura S, et al. Clinical significance of the coronary calcification score by multidetector row computed tomography for the evaluation of coronary stenosis in Japanese patients. Circ J 2006; 70: 1122-1127. (Pubitemid 44386990)
61. Schroeder S, Kuettner A, Leitritz M, et al. Reliability of differentiating human coronary plaque morphology using contrast-enhanced multislice spiral computed tomography: a comparison with histology. J Comput Assist Tomogr 2004; 28: 449-454. (Pubitemid 38988810)
62. Inoue F, Sato Y, Matsumoto N, et al. Evaluation of plaque texture by means of multislice computed tomography in patients with acute coronary syndrome and stable angina. Circ J 2004; 68: 840-844. (Pubitemid 39243805)
63. Miller JM, Rochitte CE, Dewey M, et al. Diagnostic performance of coronary angiography by 64-row CT. N Engl J Med 2008; 359: 2324-2336.
64. Ropers D, Rixe J, Anders K, et al. Usefulness of multidetector row spiral computed tomography with 64- x 0.6-mm collimation and 330-ms rotation for the noninvasive detection of significant coronary artery stenoses. Am J Cardiol 2006; 97: 343-348. (Pubitemid 43133047)
65. Fine JJ, Hopkins CB, Ruff N, et al. Comparison of accuracy of 64-slice cardiovascular computed tomography with coronary angiography in patients with suspected coronary artery disease. Am J Cardiol 2006; 97: 173-174. (Pubitemid 43139230)
66. Dodd JD, Rieber J, Pomerantsev E, et al. Quantification of nonculprit coronary lesions: comparison of cardiac 64-MDCT and invasive coronary angiography. AJR Am J Roentgenol 2008; 191: 432-438.
67. Brenner DJ, Hall EJ. Computed tomography-an increasing source of radiation exposure. N Engl J Med 2007; 357: 2277-2284.
68. Yuan C, Mitsumori LM, Beach KW, et al. Carotid atherosclerotic plaque: noninvasive MR characterization and identification of vulnerable lesions. Radiology 2001; 221: 285-299. (Pubitemid 33043408)
69. Kwong RY, Chan AK, Brown KA, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation 2006; 113: 2733-2743. (Pubitemid 43947991)
70. Trivedi RA, Mallawarachi C, JM UK-I, et al. Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler Thromb Vasc Biol 2006; 26: 1601-1606. (Pubitemid 44288989)
71. Tang T, Howarth SP, Miller SR, et al. Assessment of inflammatory burden contralateral to the symptomatic carotid stenosis using high-resolution ultrasmall, superparamagnetic iron oxide-enhanced MRI. Stroke 2006; 37: 2266-2270. (Pubitemid 44337167)
72. Okane K, Ibaraki M, Toyoshima H, et al. 18F-FDG accumulation in atherosclerosis: use of CT and MR co-registration of thoracic and carotid arteries. Eur J Nucl Med Mol Imaging 2006; 33: 589-594.
73. Nahrendorf M, Zhang H, Hembrador S, et al. Nano-particle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 2008; 117: 379-387.
74. Raylman RR, Wahl RL. Evaluation of ion-implanted- silicon detectors for use in intraoperative positron- sensitive probes. Med Phys 1996; 23: 1889-1895.
75. Nabi HA, Zubeldia JM. Clinical applications of (18)F-FDG in oncology. J Nucl Med Technol 2002; 30: 3-9; quiz 10-11
76. Ogawa M, Ishino S, Mukai T, et al. (18)F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. J Nucl Med 2004; 45: 1245-1250. (Pubitemid 47611672)
77. Chen W, Bural GG, Torigian DA, et al. Emerging role of FDG-PET/CT in assessing atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging 2009; 36: 144-151.
78. Groen HC, Gijsen FJ, van der Lugt A, et al. High shear stress influences plaque vulnerability Part of the data presented in this paper were published in Stroke 2007;38:2379-81. Neth Heart J 2008; 16: 280-283.
79. Huang X, Yang C, Yuan C, et al. Patient-Specific Artery Shrinkage and 3D Zero-Stress State in Multi- Component 3D FSI Models for Carotid Atherosclerotic Plaques Based on In Vivo MRI Data. Mol Cell Biomech 2009; 6: 121-134.
80. Kerwin WS, Liu F, Yarnykh V, et al. Signal features of the atherosclerotic plaque at 3.0 Tesla versus 1.5 Tesla: impact on automatic classification. J Magn Reson Imaging 2008; 28: 987-995.
81. Tang D, Yang C, Mondal S, et al. A negative correlation between human carotid atherosclerotic plaque progression and plaque wall stress: in vivo MRI-based 2D/3D FSI models. J Biomech 2008; 41: 727-736.
82. Yuan C, Oikawa M, Miller Z, et al. MRI of carotid atherosclerosis. J Nucl Cardiol 2008; 15: 266-275.
83. Zhao X, Miller ZE, Yuan C. Atherosclerotic plaque imaging by carotid MRI. Curr Cardiol Rep 2009; 11: 70-77.
84. Davies MJ. The contribution of thrombosis to the clinical expression of coronary atherosclerosis. Thromb Res 1996; 82: 1-32. (Pubitemid 26145261)
85. Spuentrup E, Buecker A, Katoh M, et al. Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrin-targeted contrast agent. Circulation 2005; 111: 1377-1382. (Pubitemid 40396803)
86. Botnar RM, Buecker A, Wiethoff AJ, et al. In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent. Circulation 2004; 110: 1463-1466.
87. Overoye-Chan K, Koerner S, Looby RJ, et al. EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus. J Am Chem Soc 2008; 130: 6025-6039. (Pubitemid 351620850)
88. Spuentrup E, Botnar RM, Wiethoff AJ, et al. MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients. Eur Radiol 2008; 18: 1995-2005.
89. von zur Muhlen C, von Elverfeldt D, Moeller JA, et al. Magnetic resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis. Circulation 2008; 118: 258-267.
90. Kolodgie FD, Gold HK, Burke AP, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003; 349: 2316-2325.
91. Sluimer JC, Gasc JM, van Wanroij JL, et al. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol 2008; 51: 1258-1265.
92. Virmani R, Kolodgie FD, Burke AP, et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005; 25: 2054-2061. (Pubitemid 41416300)
93. O'Malley SM, Vavuranakis M, Naghavi M, et al. Intravascular ultrasound-based imaging of vasa vasorum for the detection of vulnerable atherosclerotic plaque. Med Image Comput Comput Assist Interv Int Conf Med Image Comput Comput Assist Interv 2005; 8: 343-351. (Pubitemid 43828269)
94. Kerwin W, Hooker A, Spilker M, et al. Quantitative magnetic resonance imaging analysis of neovasculature volume in carotid atherosclerotic plaque. Circulation 2003; 107: 851-856. (Pubitemid 36241043)
95. Burtea C, Laurent S, Murariu O, et al. Molecular imaging of alpha v beta3 integrin expression in atherosclerotic plaques with a mimetic of RGD peptide grafted to Gd-DTPA. Cardiovasc Res 2008; 78: 148-157.